CAMP4 Therapeutics Corporation
CAMPHealthcare|Biotechnology|US
$4.06
+0.34 (+9.14%)
Tangible Book / Share
$1.36
Cash / Share
$1.58
Financials
Financial Snapshot
Market Cap
$254.8M
Enterprise Value
$136.7M
Revenue (TTM)
$3.4M
Net Income (TTM)
-$121.1M
Cash & Investments
$124.5M
Net Cash
$118.1M
Free Cash Flow (TTM)
-$26.4M
Operating CF (TTM)
-$25.5M
Debt/Equity
0.06
Cash Runway & Burn Rate
Cash on Hand
$124.5M
Quarterly Burn
$6.4M
Monthly Burn
$2.1M
Est. Runway
~19.5 quarters
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Cash & Investments | $38.4M | $64.0M | $109.5M | $124.5M | |
| Operating Cash Flow | -$44.2M | -$45.6M | -$29.6M | -$25.5M | |
| Free Cash Flow | -$44.8M | -$46.0M | -$29.8M | -$26.4M | |
| Capital Expenditure | -$678.0K | -$441.0K | -$279.0K | -$869.0K | |
| Financing Cash Flow | $301.0K | $71.7M | $75.9M | $75.7M |
R&D Spending
R&D (TTM)
$40.2M
R&D Intensity
1176.5%
R&D Growth vs Prior
+5.4%
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $350.0K | $652.0K | $3.5M | $3.4M | |
| R&D Expense | $40.6M | $38.8M | $38.2M | $40.2M | |
| R&D % of Revenue | 11604.6% | 5953.5% | 1092.1% | 1176.5% | |
| SG&A | $11.6M | $14.9M | $17.4M | $17.8M |
Income Statement
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $350.0K | $652.0K | $3.5M | $3.4M | |
| Cost of Revenue | $0.00 | $0.00 | $1.6M | $520.0K | |
| Gross Profit | $350.0K | $652.0K | $1.9M | $2.9M | |
| R&D | $40.6M | $38.8M | $38.2M | $40.2M | |
| SG&A | $11.6M | $14.9M | $17.4M | $17.8M | |
| Operating Income | -$51.9M | -$53.1M | -$52.1M | -$53.3M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$49.3M | -$51.8M | -$80.4M | -$121.1M | |
| Net Income | -$49.3M | -$51.8M | -$80.4M | -$121.1M | |
| EPS (Diluted) | -4.07 | -2.66 | -2.65 | -2.05 | |
| EBITDA | -$50.2M | -$51.4M | -$50.4M | -$72.0M | |
| Shares Out. (M) | 12.12 | 19.51 | 30.38 | 78.95 |
Balance Sheet
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Cash & Equivalents | $38.4M | $64.0M | $109.5M | $124.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $40.0M | $66.4M | $114.1M | $127.5M | |
| Total Assets | $54.9M | $78.3M | $117.8M | $134.0M | |
| Total Current Liabilities | $7.8M | $9.6M | $15.5M | $19.9M | |
| Long-Term Debt | $0.00 | $0.00 | $1.7M | $4.8M | |
| Total Liabilities | $178.7M | $15.2M | $70.1M | $26.9M | |
| Stockholders' Equity | -$123.7M | $63.1M | $47.7M | $107.1M | |
| Retained Earnings | -$160.0M | -$211.8M | -$292.2M | -$373.0M |
Cash Flow Statement
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Operating Cash Flow | -$44.2M | -$45.6M | -$29.6M | -$25.5M | |
| Capital Expenditure | -$678.0K | -$441.0K | -$279.0K | -$869.0K | |
| Free Cash Flow | -$44.8M | -$46.0M | -$29.8M | -$26.4M | |
| Investing Cash Flow | -$678.0K | -$441.0K | -$243.0K | -$869.0K | |
| Financing Cash Flow | $301.0K | $71.7M | $75.9M | $75.7M | |
| Issuance of Stock | $0.00 | $0.00 | $61.2M | $44.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $116.0K | -$824.0K | -$208.0K | -$18.0K | |
| Stock Based Comp. | $2.9M | $4.0M | $4.0M | $6.6M | |
| Net Change in Cash | -$44.5M | $25.7M | $46.1M | $49.3M |
Dilution Tracker
Shares outstanding grew 150.6% over 5 years — significant dilution
Shares Outstanding
63M
5-Year Share Growth
+150.6%
Stock Issuance (TTM)
$44.1M
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Shares Out. (M) | 12.12 | 19.51 | 30.38 | 78.95 | |
| Change vs Prior % | — | 60.9% | 55.8% | 159.9% | |
| Stock Issuance | $0.00 | $0.00 | $61.2M | $44.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.9M | $4.0M | $4.0M | $6.6M |
Margins & Profitability
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 53.1% | 84.8% | |
| Operating Margin % | -14822.6% | -8142.3% | -1488.3% | -1556.7% | |
| Net Margin % | -14083.1% | -7943.4% | -2298.5% | -3539.9% | |
| EBITDA Margin % | -14343.1% | -7882.2% | -1441.5% | -2104.6% | |
| FCF Margin % | -12809.4% | -7055.7% | -852.8% | -771.9% | |
| ROE % | 39.8% | -82.0% | -168.5% | -261.8% | |
| ROA % | -89.7% | -66.1% | -68.2% | -90.4% | |
| ROIC % | -103.4% | -73.9% | -50.8% | -46.0% | |
| R&D / Revenue % | 11604.6% | 5953.5% | 1092.1% | 1176.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0.0% | 86.3% | 436.5% | |
| Gross Profit | 0.0% | 86.3% | 185.1% | |
| Operating Income | 0.0% | -2.3% | 1.9% | |
| Net Income | 0.0% | -5.1% | -55.2% | |
| EPS (Diluted) | 0.0% | 34.6% | 0.4% | |
| Operating Cash Flow | 0.0% | -3.2% | 35.1% | |
| Free Cash Flow | 0.0% | -2.6% | 35.2% | |
| R&D Expense | 0.0% | -4.4% | -1.6% | |
| SG&A Expense | 0.0% | 28.5% | 16.3% | |
| Total Assets | 0.0% | 42.5% | 50.4% | |
| Book Value / Share | 0.0% | 131.7% | -51.5% | |
| Debt | 0.0% | -26.0% | -77.2% | |
| Diluted Shares | 0.0% | 60.9% | 55.8% |
Valuation
P/E (TTM)At Loss
P/S74.47
10Y Low / Med / High53.24 / 156.16 / 371.36
P/B2.99
EV/EBITDAAt Loss
EV/Revenue39.96
10Y Low / Med / High22.50 / 71.21 / 295.12
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$1.36
Net Current Assets / Share
$1.60
Graham Net-Net
$1.24
Cash / Share
$1.58
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| P/E Ratio | -2.63 | -1.96 | -2.31 | -1.98 | |
| P/S Ratio | 371.36 | 156.16 | 53.24 | 74.47 | |
| P/B Ratio | -1.05 | 1.61 | 3.90 | 2.99 | |
| EV/EBITDA | -2.06 | -0.90 | -1.56 | -1.90 | |
| EV/Revenue | 295.12 | 71.21 | 22.50 | 39.96 |
Analyst Estimates & Quality
Altman Z-Score
0.96
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $6.0M | $4.9M | $2.2M |
| Net Income | -$32.4M | -$23.4M | -$23.4M |
| EPS | $-1.16 | $-0.80 | $-0.75 |
| # Analysts (EPS) | 7 | 7 | 8 |
Revenue Segments
By Product
| Segment | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Software And Subscription Services | $63.8M | — | — | — | — | — |
| Telematics Systems | $302.1M | — | — | — | — | — |
| Application Subscriptions And Related Products And Other Services | — | $77.9M | $124.9M | — | — | — |
| Product | — | $285.9M | — | $193.5M | $182.9M | $188.9M |
| Telematics Products | — | — | $241.2M | — | — | — |
| Application Subscriptions And Other Services | — | — | — | $115.1M | $112.9M | $106.1M |
By Geography
| Segment | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| All Other | $5.9M | $6.9M | $14.1M | $10.1M | $3.1M | $4.3M |
| Asia Pacific | $12.9M | $14.0M | $9.2M | $12.3M | $19.0M | $18.4M |
| CANADA | $15.0M | $9.8M | — | — | — | — |
| Europe Middle East And Africa | $45.8M | — | — | — | — | — |
| South America | $20.7M | $15.1M | $21.2M | $27.1M | — | — |
| UNITED STATES | $265.6M | $268.5M | $266.4M | $200.7M | $197.2M | $185.5M |
| E M E A | — | $49.5M | $55.2M | $58.5M | $51.8M | — |
| L A S F | — | — | — | — | $24.8M | — |
| EMEA | — | — | — | — | — | $54.7M |
| Latin America | — | — | — | — | — | $32.0M |